What is the recommended dose of Ertapenem for patients with Impaired renal function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ertapenem Dosing in Renal Impairment

For patients with severe renal impairment (creatinine clearance ≤30 mL/min/1.73 m²) or end-stage renal disease, reduce the ertapenem dose to 500 mg once daily. 1

Standard Dosing for Reference

  • Patients with normal renal function (creatinine clearance >90 mL/min/1.73 m²) receive 1 gram once daily intravenously or intramuscularly 1
  • No dosage adjustment is necessary for patients with creatinine clearance >30 mL/min/1.73 m² 2, 1

Dose Adjustments Based on Renal Function

Mild to Moderate Renal Impairment

  • Creatinine clearance 31-90 mL/min/1.73 m²: Continue standard 1 gram once daily dosing without adjustment 1, 3
  • Patients with mild renal impairment (CLCR 60-90 mL/min/1.73 m²) show only a 1.5-fold increase in unbound drug exposure, which does not warrant dose reduction 1
  • Moderate renal impairment (CLCR 31-59 mL/min/1.73 m²) results in a 2.3-fold increase in unbound AUC but remains within acceptable therapeutic range 1

Severe Renal Impairment and ESRD

  • Creatinine clearance ≤30 mL/min/1.73 m²: Reduce dose to 500 mg once daily 2, 1
  • End-stage renal disease (CLCR <10 mL/min/1.73 m²): Use 500 mg once daily 1, 3
  • The rationale for dose reduction is that unbound drug exposure increases 4.4-fold in advanced renal impairment and 7.6-fold in ESRD compared to healthy subjects 1

Hemodialysis Considerations

If ertapenem is administered within 6 hours prior to hemodialysis, give a supplementary dose of 150 mg following the dialysis session. 2, 1

  • Hemodialysis removes approximately 30% of the administered ertapenem dose during a 4-hour session 1, 3
  • If ertapenem is given at least 6 hours before hemodialysis, no supplementary dose is needed 1
  • The 150 mg supplementary dose represents 30% of the reduced daily dose (500 mg) for patients with severe renal impairment 3

Important Clinical Considerations

Calculating Creatinine Clearance

  • When only serum creatinine is available, use the Cockcroft-Gault equation to estimate creatinine clearance 1:
    • Males: (weight in kg) × (140 - age in years) / [(72) × serum creatinine (mg/100 mL)]
    • Females: 0.85 × (value calculated for males)
  • Serum creatinine must represent steady-state renal function for accurate estimation 1

Pediatric Patients

  • There are no data available for dose adjustments in pediatric patients with renal impairment 1
  • Standard pediatric dosing (15 mg/kg twice daily, not to exceed 1 g/day) applies only to those with normal renal function 1

Common Pitfalls to Avoid

  • Do not use dextrose-containing diluents for reconstitution or dilution of ertapenem 1
  • Failing to provide the supplementary post-hemodialysis dose when ertapenem is given within 6 hours of dialysis 1
  • Assuming that less frequent dosing maintains adequate time above MIC in critically ill patients, who may have altered pharmacokinetics beyond renal impairment alone 4
  • In critically ill patients with severe sepsis and normal renal function, standard dosing may still result in suboptimal drug concentrations due to increased volume of distribution and altered protein binding 5

Monitoring Recommendations

  • Monitor clinical response closely in patients with fluctuating renal function 4
  • The half-life of ertapenem increases from 4.5 hours in healthy subjects to 10.6 hours in advanced renal impairment and 14.1 hours in ESRD 1, 3

References

Guideline

Ertapenem Dosing and Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Faropenem Pharmacokinetics and Clinical Considerations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.